TCRT Stock Pops On Volatile Spike As Traders Circle

Alaunos Therapeutics Inc. stocks have been trading up by 41.78 percent, driven by strong positive sentiment from recent biotech trial headlines.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TCRT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Recent TCRT trading shows a sharp intraday spike from the low $1s into the $2s, attracting momentum-focused traders.
Daily TCRT chart reveals a pullback from late-August highs near $1.79, with recent support forming around the mid-$1.50s.
Alaunos Therapeutics Inc. carries tiny revenue, heavy losses, and a high price-to-sales ratio, keeping TCRT firmly in high-risk territory.
Weak liquidity, negative cash flow, and a thin cash balance mean TCRT traders must respect risk and manage position size tightly.

Quick Financial Overview

Alaunos Therapeutics Inc., traded under ticker TCRT, is a classic high-risk biotech-style story stock. The financials tell a tough tale. The company booked only about $5,000 in revenue over the most recent period, yet sports a sky‑high price-to-sales ratio above 1,500. That means traders are paying a steep premium for future hopes, not present business strength.

TCRT’s margins are deep in the red. Pretax profit margin sits around -3,348%, and returns on equity and assets are also heavily negative. Alaunos Therapeutics Inc. reported roughly -$952,000 in quarterly net loss, with free cash flow at about -$300,000. This is not a cash-generating machine; it’s burning capital to keep the story alive.

More Breaking News

The balance sheet is thin. TCRT shows about $124,000 in cash against total liabilities near $864,000 and a working capital deficit around -$198,000. Current ratio is 0.8 and quick ratio just 0.1, signaling real liquidity stress. On the positive side, Alaunos Therapeutics Inc. carries no long-term debt, which limits interest burden. For active traders, these numbers frame TCRT as a pure trading vehicle, not a fundamentals play.

Why Traders Are Watching TCRT Price Action

Despite the rough fundamentals, TCRT continues to draw active traders because the chart is alive. The multi-day daily chart shows Alaunos Therapeutics Inc. trading in the $1.60–$1.80 area through late August, topping near $1.79–$1.80 and then slipping. Recent closes around $1.49–$1.60 suggest a slow grind lower from that late-summer push, but not a total breakdown. That kind of controlled pullback often becomes a launchpad if fresh momentum steps in.

The intraday 5‑minute data is where TCRT really gets interesting. Alaunos Therapeutics Inc. ripped from sub‑$2 premarket to a high over $3.10 around 05:00, before fading back into the mid‑$2s. That’s a huge range in a few hours. For TCRT traders, this is textbook volatility: range expansion, emotional moves, and big liquidity pockets as scalpers pile in and out.

Alaunos Therapeutics Inc. then settled into a choppy band between roughly $2.20 and $2.40 later in the premarket, with repeated pops toward $2.36–$2.38 and quick pullbacks. That intraday behavior on TCRT says one thing clearly: day traders are in control, not long-term holders. Every spike is getting sold, but every dip finds a bidder.

For pattern-focused traders, TCRT now sits at an inflection zone. On the daily, Alaunos Therapeutics Inc. is holding above recent lows, while the intraday chart shows it can squeeze hard when volume hits. The setup many will watch is simple: a clean break above the morning spike area with volume for a potential second leg, or a failure at that zone that turns into a sharp fade.

Conclusion

TCRT is a reminder of what Tim Sykes hammers on day after day: volatile, low-priced names can offer huge opportunity, but only for disciplined traders. Alaunos Therapeutics Inc. has tiny revenue, heavy losses, and a stressed balance sheet. The fundamentals say caution. Yet the tape tells a different, very tradable story. When TCRT ramps from under $2 to over $3 in minutes, that’s exactly the kind of volatility short-term traders hunt.

The key is to treat Alaunos Therapeutics Inc. as a trading vehicle, not a long-term safety net. TCRT’s negative cash flow, low cash balance, and weak liquidity ratios mean dilution or financing risk always lurks in the background. That overhang can crush a slow, stubborn trader. Momentum players should focus on clear intraday levels, volume surges, and tight risk. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” That perspective fits TCRT perfectly: the goal is to survive the wild swings first, and only then to capitalize on them.

As Tim Sykes likes to say, “Cut losses quickly and never fall in love with a stock.” TCRT is the kind of name that rewards that mindset. Alaunos Therapeutics Inc. can move fast in both directions, shaking out anyone who hesitates. For serious traders who study the chart, respect the risk, and stay nimble, TCRT remains a high-volatility classroom for real-world trading lessons, not a buy‑and‑forget story.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!